Swiss pharma major Novartis is proposing to purchase
all outstanding shares in Swiss biopharmaceutical firm Speedel following
its acquisition in early July of a further 51.7% share, which gives it a
61.4% holding.
by Eisberg, Neil
Swiss pharma major Novartis is proposing to purchase all
outstanding shares in Swiss biopharmaceutical firm Speedel following its
acquisition in early July of a further 51.7% share, which gives it a
61.4% holding. The complete acquisition, excluding the 9.7% stake
previously held by Novartis, is valued at CHF907m. Novartis believes the
full acquisition is a natural development of the two companies'
long-standing collaboration.
COPYRIGHT 2008 Society of Chemical
Industry Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2008 Gale, Cengage Learning. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.